Medolife Rx, Inc. Has Submitted Applications Of Their Scorpion Venom To Help Fight Against Cancer And COVID-19 With The FDA In The Dominican Republic;
The FDA Is In The Process Of Investigation And Conducting Their Due Diligence For Efficacy And Safety
Patented Polarization Technology Brings Increased Effectiveness in Venom-To-Drug Development
BURBANK, Calif., Jan. 21, 2021 /PRNewswire/ -- Medolife Rx, Inc., ("Medolife") the majority owner of Quanta, Inc. (OTCPK: QNTA) today announced that Medolife and The Ministry of Environment of The Dominican Republic signed an exclusive 10-year agreement with automatic renewal. This groundbreaking partnership encompasses exclusive rights for investigations, production, and distribution world-wide for the venom of a unique species of scorpions indigenous to the Dominican Republic. Medolife will focus on the R&D of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals, using its proprietary process of its polarization technology, developed by CEO, Dr. Arthur Mikaelian.
A recent Business Insider article estimated scorpion venom to be the most expensive liquid in the world, valued at $39 million dollars-per-gallon. Scorpion venom is currently in active research by large pharmaceutical companies for its therapeutic use in treating cancer, COVID-19, viral diseases, inflammation, and pain, all of which are independently multi-billion-dollar industries. Medolife is a pioneer in venom-to-drug development. With Medolife's Dominican Republic Scorpion Reservation being one of the largest natural breeding grounds for scorpions on earth. Medolife will bring its 30+ years of research and expertise to help locate, study and develop groundbreaking formulas and pharmaceutical-grade medications for consumer use. This agreement also allows for Medolife to expand its existing infrastructure, facilities, and certified pharmaceutical lab.
Medolife's close relationship with the Dominican Republic government dates back to 2007, which significantly contributed to research and FDA trials of a new generation of natural pharmaceutical-grade and evidence-based nutraceutical products. Medolife CEO, Dr. Arthur Mikaelian said "We could not feel more humbled by the trust the Dominican Republic Government has shown to us. We have worked closely with them for the past 14 years and are incredibly excited to continue our research and trials with them as a partner for the next 10-years and beyond." He continued by saying "This partnership has the possibilities to bring so many new life-changing formulas to the world. From cancer medications to viral and immune system therapies, we are truly just scratching the surface of what this incredible peptide can do for mankind."
Over the years, The Government of The Dominican Republic and Medolife have undertaken extensive research and expeditions to locate and identify specific scorpion species that have therapeutic and medical values. Marina Hernandez, Head of the Genetic Resources Department of the Biodiversity Directorate with the Dominican Republic Ministry of Environment said "A long term partnership between our Government and Medolife gives us much hope. We have experienced first-hand the marvelous results Dr. Mikaelian has discovered through his research. With our ongoing support of Medolife's research, we wish to contribute to the significant improvement of the lives of people in the Dominican Republic, and the world at large."
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.buyquanta.com/
818-659-8052
View original content:SOURCE Quanta, Inc.
Company Codes: OTC-PINK:QNTA, OtherOTC:QNTA